11
2020-09
Among them, Kintor Pharmaceutical Limited was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020".
01
2020-09
Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK
In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including Kintor Pharmaceutical Limited (stock code: 9939.HK).
01
2020-09
Three Parties Jointly Build A Precise Cancer Treatment Platform
(September 1, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) signed a strategic cooperation framework agreement with Suzhou GloriousMed Biomedical Group Co., Ltd. (hereinafter referred to as “GloriousMed”) and HM Shuke (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “HM Healthcare”), under which the three parties will create a patient-centered, integrated precise cancer treatment platform.
01
2020-09
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
On 28 August 2020, Kintor Pharmaceutical Limited (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.
24
2020-08
First Patient Enrolment for the COVID-19 Clinical Trial of Proxalutamide Completed
(August 24, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) , declared that the Clinical Trial (identifier: NCT04446429) to conduct research for Proxalutamide (GT0918) as a treatment for the coronavirus disease (“COVID-19”)has recorded the first patient enrolment in Brazil. The Company plans to enrol a total of 381 subjects and it’s expected that the enrolment will be completed in 2 months.
23
2020-08
Kintor Pharmaceutical Limited Announces 2020 Interim Results
(August 23, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939.HK, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other indications. The Company was pleased to announce its recent business highlights and the financial results for the six months ended 30 June 2020 (the “Reporting Period”).
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn